Galecto (NASDAQ: GLTO)
$3.32
(-1.0%)
-$0.04
Price as of June 16, 2025, 4:00 p.m. ET
Galecto Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Galecto Company Info
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3, lysyl oxidase-like 2, and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.